Agilent SureSelect Human All Exon V8.

High-performance exome for the enrichment of human coding regions, with updated coverage of RefSeq, CCDS and GENCODE, including the TERT promoter and difficult-to-capture exons.

3.- Detailed Description

Operating principle

SureSelect Human All Exon V8 is based on NGS library preparation and capture enrichment of target regions of the human exome.

The workflow is compatible with Agilent SureSelect systems and can be integrated into manual or automated protocols, depending on the laboratory configuration.

Clinical applications

Product intended for laboratories performing exome sequencing in genomic research, clinical genetics or molecular biology projects, especially when broad and uniform coverage of human coding regions is required.

Benefits

Complete and updated coverage of coding regions from RefSeq, CCDS and GENCODE, including the TERT promoter and difficult-to-capture exons. Probe design based on machine learning to improve coverage, efficiency and uniformity, including difficult-to-capture exons and the TERT promoter. Efficient design size, aimed at reducing sequencing requirements and costs per sample. Automation compatibility with the Bravo Automated Liquid Handling Platform and Magnis NGS Prep System.

Results or key indicators

Panel coverage: target region of 35.1 Mb and design size of 41.6 Mb. Target sequence coverage in 8-plex captures: 96% of bases ≥20X, 93% ≥30X, 86% ≥40X and 74% ≥50X, with a median read coverage of 63X.
Image 1
Uniform distribution of coverage across the GC content spectrum.
Image 2
Image 3
Coverage of clinical interest:
100% of the coding content of CCDS, GENCODE and RefSeq. 179,645 RefSeq exons ≥20X and 14,168 RefSeq genes ≥20X; in ACMG 59 genes, 1,009 exons ≥20X.
Image 4
Genes associated with rare diseases: 6,003 exons ≥20X, with 24% more genes completely covered at ≥20X
Image 5

Technology used

The NGS workflow is based on library preparation and capture enrichment using Agilent SureSelect systems.

Possibility of integration into SureSelectXT HS2, SureSelectXT HS, SureSelectXT Low Input, SureSelectQXT and SureSelectXT legacy workflows Automation on the Agilent Bravo Automated Liquid Handling platform and Agilent Magnis NGS Prep system.
Image 6

Intended audience/user

The product is intended for genetics and molecular biology laboratories that require a scalable whole-exome workflow compatible with automation.

Considerations or limitations

RUO label (For Research Use Only)

4.- Key Aspects

Human exome with a target region of 35.1 Mb and an efficient design of 41.6 Mb.
Updated coverage of coding regions from RefSeq, CCDS and GENCODE.
Includes the TERT promoter and difficult-to-capture exons.
Probe design based on machine learning and an optimised manufacturing process.
Uniform coverage across the GC spectrum, supporting the representation of GC-rich and GC-poor regions.
High enrichment performance, with improved sequencing efficiency under the conditions evaluated by Agilent.
Compatible with manual and automated workflows, including Bravo and Magnis.
Image 7
5.- Presentation Details

Main formats indicated for SureSelect Human All Exon V8:

Compatible with rapid hybridisation

Product 16 Rxns 96 Rxns 96 Rxns Auto
SureSelect XT HS Human All Exon V8 5191-6873 5191-6874 5191-6875

*Pre-Capture Formats

Product 2 Hybs 12 Hybs 12 Hybs Auto
SureSelect XT HS PreCap Human All Exon V8 5191-6876 5191-6877 5191-6878

Compatible with overnight hybridisation

Product 16 Rxns 96 Rxns 96 Rxns Auto
SureSelect XT Human All Exon V8 5191-6879 5191-6891 5191-6892

*Pre-Capture Formats

Product 2 Hybs 12 Hybs 12 Hybs Auto
SureSelect XT PreCap Human All Exon V8 5280-0032 5280-0033 5280-0034

Compatible with Magnis NGS Prep System

Product 32 Rxns 96 Rxns
Magnis SSEL XT HS Human All Exon V8, Rev B G9772C G9772D
Magnis SSEL XT HS2 Human All Exon V8, Rev B G9774A G9774B

Area:

Exomes, Hereditary and/or Rare Diseases, Molecular Genetics

Brand:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

SureSelect Cancer CGP Assay

Targeted-enrichment NGS pan-cancer panel for comprehensive genomic profiling (CGP) of solid tumours. Designed to detect somatic variants at DNA level (SNVs, indels, CNVs, translocations) and RNA level (gene fusions), as well as to assess complex immuno-oncology biomarkers such as tumour mutational burden (TMB), microsatellite instability (MSI) and homologous recombination deficiency (HRD). Detailed Description Operating principle…
Agilent
Next Generation Sequencing (NGS)

SeqOne HRD Solution con Agilent SureSelect CD HRR17 Panel

HRD analysis solution combining low-coverage whole-genome sequencing (shallow/low-pass WGS) and a targeted gene panel to detect genomic instability, BRCA1/2 alterations and other genes related to homologous recombination. It is designed for laboratories wishing to implement HRD testing in-house with an automated, efficient and clinically validated workflow. Detailed Description SeqOne’s HRD solution combines shallow WGS and…
Agilent
Next Generation Sequencing (NGS)

OncoSELECT®

Comprehensive targeted liquid biopsy assay designed to support decision-making in oncology through the analysis of 74 clinically relevant genes. The solution encompasses everything from library preparation reagents to bioinformatics analysis, clinical interpretation and the generation of detailed reports. 3.- Detailed Description Operating principle OncoSELECT® is an advanced liquid biopsy panel based on circulating cell-free DNA…
OncoDNA
Next Generation Sequencing (NGS)

Duplicα RealTime ApoE Genotyping Kit

In vitro diagnostic kit based on real-time PCR for the qualitative detection of the ApoE*E2, ApoE*E3 and ApoE*E4 alleles in human genomic DNA. Detailed Description Operating principle The kit is based on the specific amplification of target sequences by Real-Time PCR, using specific fluorescent probes. Allelic discrimination is performed using labelled probes: FAM (6-carboxyfluorescein) to…
Clonit
Real Time PCR (qPCR)